JP2024517942A - Gタンパク質共役受容体の調節剤 - Google Patents

Gタンパク質共役受容体の調節剤 Download PDF

Info

Publication number
JP2024517942A
JP2024517942A JP2023569936A JP2023569936A JP2024517942A JP 2024517942 A JP2024517942 A JP 2024517942A JP 2023569936 A JP2023569936 A JP 2023569936A JP 2023569936 A JP2023569936 A JP 2023569936A JP 2024517942 A JP2024517942 A JP 2024517942A
Authority
JP
Japan
Prior art keywords
compound
group
independently selected
optionally substituted
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517942A5 (cg-RX-API-DMAC10.html
Inventor
ダニエル アーランソン
レイモンド ブイ. フッチニ
スティグ ハンセン
ジェフ アイウィッグ
シャム クリシュナン
エンリケ モヤ
スティーヴン セトファー
Original Assignee
カーモット セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カーモット セラピューティクス インコーポレイテッド filed Critical カーモット セラピューティクス インコーポレイテッド
Publication of JP2024517942A publication Critical patent/JP2024517942A/ja
Publication of JP2024517942A5 publication Critical patent/JP2024517942A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Holo Graphy (AREA)
  • Gyroscopes (AREA)
  • Amplifiers (AREA)
JP2023569936A 2021-05-13 2022-05-13 Gタンパク質共役受容体の調節剤 Pending JP2024517942A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188342P 2021-05-13 2021-05-13
US63/188,342 2021-05-13
PCT/US2022/029305 WO2022241287A2 (en) 2021-05-13 2022-05-13 Modulators of g-protein coupled receptors

Publications (2)

Publication Number Publication Date
JP2024517942A true JP2024517942A (ja) 2024-04-23
JP2024517942A5 JP2024517942A5 (cg-RX-API-DMAC10.html) 2025-05-22

Family

ID=82019613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569936A Pending JP2024517942A (ja) 2021-05-13 2022-05-13 Gタンパク質共役受容体の調節剤

Country Status (20)

Country Link
US (2) US12281149B2 (cg-RX-API-DMAC10.html)
EP (1) EP4337682A2 (cg-RX-API-DMAC10.html)
JP (1) JP2024517942A (cg-RX-API-DMAC10.html)
KR (1) KR20240007251A (cg-RX-API-DMAC10.html)
CN (1) CN117980325A (cg-RX-API-DMAC10.html)
AU (1) AU2022272251A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023023559A2 (cg-RX-API-DMAC10.html)
CA (1) CA3220005A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003369A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023015805A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230530A (cg-RX-API-DMAC10.html)
DO (1) DOP2023000247A (cg-RX-API-DMAC10.html)
EC (1) ECSP23093673A (cg-RX-API-DMAC10.html)
GE (1) GEAP202416419A (cg-RX-API-DMAC10.html)
IL (1) IL308392A (cg-RX-API-DMAC10.html)
JO (1) JOP20230291A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023013492A (cg-RX-API-DMAC10.html)
PE (1) PE20240890A1 (cg-RX-API-DMAC10.html)
TW (1) TW202313666A (cg-RX-API-DMAC10.html)
WO (1) WO2022241287A2 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
KR20240007251A (ko) * 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
KR20250140132A (ko) * 2023-01-18 2025-09-24 상하이 민웨이 바이오테크놀로지 씨오 엘티디 삼중 활성을 갖는 융합 단백질 및 그 용도
EP4716545A1 (en) * 2023-05-21 2026-04-01 Carmot Therapeutics Inc. Treatment of adults with overweight or obesity with or without weight-related comorbidities
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2026030653A1 (en) 2024-07-31 2026-02-05 Carmot Therapeutics Inc. Synthesis of an intermediate and its use for the preparation of glp-1r/gipr agonists
WO2026027650A1 (en) 2024-08-02 2026-02-05 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-cyano-5-fluorophenyl)-2-methyl-propionic acid
TW202620036A (zh) 2024-09-27 2026-05-16 美商卡默療法股份有限公司 肽酪胺酸-酪胺酸(pyy)類似物及glp-1r促效劑之組合療法
WO2026092581A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata
WO2026092580A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases
WO2026099325A1 (en) * 2024-11-08 2026-05-15 F. Hoffmann-La Roche Ag X-β-ALA-GLU(OTBU)-GLY TETRAMER AND ITS USE IN SPPS SYNTHESIS
WO2026112366A1 (en) * 2024-11-20 2026-05-28 Carmot Therapeutics Inc. Treatment of steatotic liver disease associated with metabolic dysfunction
WO2026119942A1 (en) * 2024-12-05 2026-06-11 F. Hoffmann-La Roche Ag Synthesis of a peptide including stepwise sidechain preparation
WO2026119946A1 (en) * 2024-12-05 2026-06-11 F. Hoffmann-La Roche Ag Spps synthesis of a peptide with bsmoc-lys building block
WO2026119941A1 (en) * 2024-12-05 2026-06-11 F. Hoffmann-La Roche Ag Spps synthesis of a peptide comprising a fatty acid side chain
WO2026125207A1 (en) * 2024-12-09 2026-06-18 F. Hoffmann-La Roche Ag Process for the preparation of a x-beta-ala-glu(otbu)-gly tetramer by lpps and its use in spps synthesis
WO2026131797A2 (en) 2024-12-18 2026-06-25 F. Hoffmann-La Roche Ag Process for the preparation of a fatty acid compound
WO2026153900A1 (en) 2025-01-15 2026-07-23 F. Hoffmann-La Roche Ag Process for the preparation of a bsmoc-lys fatty acid compound
CN119930843B (zh) * 2025-01-22 2025-12-30 北京康乐卫士生物技术股份有限公司 具有glp和gip双重活性的融合蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534676A (ja) * 2014-09-24 2017-11-24 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インクレチン−インスリンコンジュゲート
WO2019183577A1 (en) * 2018-03-23 2019-09-26 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1137667B1 (en) 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
CN1364167A (zh) 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1235618A2 (en) 1999-09-07 2002-09-04 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
CA2607566A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
JP4094660B1 (ja) 2005-08-10 2008-06-04 武田薬品工業株式会社 糖尿病治療剤
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
JP5399244B2 (ja) 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트
CN103221404B (zh) 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
US20120021979A1 (en) 2010-06-24 2012-01-26 Vanderbilt University GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
RU2013133803A (ru) 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
CA3134906A1 (en) 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
US20150087586A1 (en) 2012-03-29 2015-03-26 Cebix, Inc. Pegylated c-peptide
CN104884056A (zh) 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
JP6548579B2 (ja) 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
US9766239B2 (en) 2013-03-13 2017-09-19 Arizona Board Of Regents On Behalf Of Arizona State University Synbodies for detection of human norovirus
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
WO2015031268A1 (en) 2013-08-26 2015-03-05 Arizona Board Of Regents On Behalf Of Arizona State University High affinity synbodies for influenza
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
EP3218414A1 (en) 2014-11-14 2017-09-20 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
AR103242A1 (es) 2015-01-09 2017-04-26 Lilly Co Eli Compuestos co-agonistas de gip y glp-1
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
GB2551945B (en) 2015-12-18 2021-09-08 Heptares Therapeutics Ltd Novel GLP-1 receptor agonist peptides
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
TWI799680B (zh) 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
CN110684082B (zh) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型glp-1/gip雙重促效劑
KR20220050820A (ko) 2020-10-16 2022-04-25 한미약품 주식회사 Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
CN116171164A (zh) 2020-10-17 2023-05-26 太阳医药工业有限公司 Glp-1/gip双重激动剂
CN114617956B (zh) 2020-12-10 2023-10-03 江苏中新医药有限公司 一种高效降糖的蛋白质药物
CN116635050A (zh) 2020-12-24 2023-08-22 韩美药品株式会社 对胰高血糖素、glp-1和gip受体全部具有活性的新型三重激动剂及其用途
KR20240007251A (ko) * 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제
IL310644A (en) 2021-08-23 2024-04-01 Lilly Co Eli Compounds and Methods for Liquid Phase Synthesis
EP4410827A4 (en) 2021-09-02 2026-04-29 Sunshine Lake Pharma Co Ltd GLP-1/GIP Dual Target Fusion Polypeptide and Protein and Their Applications
EP4436991A1 (en) 2021-11-22 2024-10-02 Sun Pharmaceutical Industries Limited Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534676A (ja) * 2014-09-24 2017-11-24 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インクレチン−インスリンコンジュゲート
WO2019183577A1 (en) * 2018-03-23 2019-09-26 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. Volume 296, Article 100133, JPN6026008917, 4 January 2021 (2021-01-04), pages 1 - 15, ISSN: 0005810823 *

Also Published As

Publication number Publication date
ECSP23093673A (es) 2024-01-31
GEAP202416419A (en) 2024-03-25
MX2023013492A (es) 2024-02-29
WO2022241287A2 (en) 2022-11-17
CA3220005A1 (en) 2022-11-17
BR112023023559A2 (pt) 2024-02-06
PE20240890A1 (es) 2024-04-24
US12281149B2 (en) 2025-04-22
EP4337682A2 (en) 2024-03-20
DOP2023000247A (es) 2024-03-28
WO2022241287A3 (en) 2022-12-29
CO2023015805A2 (es) 2023-12-11
CN117980325A (zh) 2024-05-03
AU2022272251A1 (en) 2023-11-16
CR20230530A (es) 2024-02-19
TW202313666A (zh) 2023-04-01
IL308392A (en) 2024-01-01
JOP20230291A1 (ar) 2023-11-13
US20240383960A1 (en) 2024-11-21
CL2023003369A1 (es) 2024-05-17
US20230151074A1 (en) 2023-05-18
KR20240007251A (ko) 2024-01-16

Similar Documents

Publication Publication Date Title
US12281149B2 (en) Modulators of G-protein coupled receptors
TWI840348B (zh) G蛋白偶聯受體調節劑
US12552791B2 (en) Heterocyclic GLP-1 agonists
JP2023513272A (ja) ヘテロ環glp-1アゴニスト
EP3105213B1 (en) Dihydrobenzofuran compounds useful in the treatment of diabetes and obesity
JP6380402B2 (ja) ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
EP4638440A1 (en) Heterocyclic glp-1 agonists
TW202506102A (zh) 雜環的glp-1促效劑
KR20250157491A (ko) Glp-1 효능제 활성을 갖는 화합물의 염 및 고체 형태
EA052579B1 (ru) Модуляторы сопряженных с g-белком рецепторов
EP3650440A1 (en) Benzoic ester compound
EA051684B1 (ru) Модуляторы сопряженных с g-белком рецепторов
HK40022717A (en) Benzoic ester compound
HK1227023B (en) Dihydrobenzofuran compounds useful in the treatment of diabetes and obesity
HK1227023A1 (en) Dihydrobenzofuran compounds useful in the treatment of diabetes and obesity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260603

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260622

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260729